IXORA-S 1 Ixekizumab provides superior efficacy compared to u stekinumab over 52-weeks of 1 treatment : results from IXORA-S , a phase 3 study 2

78 Background: Biologics targeting interleukin (IL)-17A allow for rapid clearance of psoriatic 79 plaques, with a clinically favorable safety profile. 80 Objectives: To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, versus 81 the IL-12/23 inhibitor, ustekinumab, through 52 weeks of treatment in the head-to-head trial, 82

[1]  L. French,et al.  Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study , 2017, The British journal of dermatology.

[2]  B. Strober,et al.  Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data , 2017, Journal of the American Academy of Dermatology.

[3]  A. Egeberg.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[4]  K. Kikly,et al.  Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A , 2016, Journal of inflammation research.

[5]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[6]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[7]  M. Lebwohl,et al.  A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. , 2014, Journal of the American Academy of Dermatology.

[8]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[9]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[10]  Jun Yan,et al.  Dermal γδ T cells--a new player in the pathogenesis of psoriasis. , 2013, International immunopharmacology.

[11]  S. Raychaudhuri.  Role of IL-17 in Psoriasis and Psoriatic Arthritis , 2013, Clinical Reviews in Allergy & Immunology.

[12]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[13]  F. Nestle,et al.  The role of IL-23 in the immunopathogenesis of psoriasis , 2010, F1000 biology reports.

[14]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[15]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[16]  A. Gottlieb,et al.  Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. , 2007, Archives of dermatology.

[17]  B. Miller,et al.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. , 2006, Journal of the American Academy of Dermatology.

[18]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[19]  C Cates,et al.  Confidence intervals for the number needed to treat , 1999 .

[20]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study , 2017, Journal of the American Academy of Dermatology.